The consistent safety and tolerability findings across trials reinforce that the potential efficacy of adding neoadjuvant P to achieve dual HER2 blockade outweighs potential risks in appropriate HER2+ early breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.